Bupropion Sustained-Release Tablets (Smoking Deterrent) and Rituximab and hyaluronidase human, recombinant Subcutaneous
Determining the interaction of Bupropion Sustained-Release Tablets (Smoking Deterrent) and Rituximab and hyaluronidase human, recombinant Subcutaneous and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: bupropion
Brand name: Aplenzin, Buproban, Forfivo XL, Wellbutrin SR, Wellbutrin XL, Zyban, Zyban Advantage Pack, Budeprion XL
Synonyms: Bupropion, BuPROPion
Generic Name: hyaluronidase / rituximab
Brand name: Rituxan Hycela
Synonyms: Hyaluronidase and rituximab, Rituximab and Hyaluronidase
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Bupropion Sustained-Release Tablets (Smoking Deterrent)-Rituximab Intravenous
- Bupropion Sustained-Release Tablets (Smoking Deterrent)-Riva-Amoxicillin
- Bupropion Sustained-Release Tablets (Smoking Deterrent)-Rivaroxaban
- Bupropion Sustained-Release Tablets (Smoking Deterrent)-Rivastigmine
- Bupropion Sustained-Release Tablets (Smoking Deterrent)-Rivastigmine Capsules
- Bupropion Sustained-Release Tablets (Smoking Deterrent)-Rivastigmine Oral Solution
- Rituximab and hyaluronidase human, recombinant Subcutaneous-Bupropion Tablets
- Rituximab and hyaluronidase human, recombinant Subcutaneous-Bupropion Tablets and Sustained-Release Tablets
- Rituximab and hyaluronidase human, recombinant Subcutaneous-Burapren Injection
- Rituximab and hyaluronidase human, recombinant Subcutaneous-Burn-O-Jel Topical application
- Rituximab and hyaluronidase human, recombinant Subcutaneous-Burnamycin Topical application
- Rituximab and hyaluronidase human, recombinant Subcutaneous-Burosumab